Orforglipron brand name: Foundayo, LY3502970 and what Canada may call it

That is the short answer. The longer one is more useful for Canadians, because the name on a Canadian box is not settled. Below we cover every name this molecule has carried, how to say them, where the generic name came from, how regulators vet a brand name, and why a fake "orforglipron" listing online should worry you. If you want the science of the drug itself, our plain-language guide to how orforglipron works covers that. We stick to names here.

Orforglipron brand name at a glance

One molecule, five labels. Most people only meet two of them, but the others turn up in trial registries, FDA documents and, unfortunately, on research-chemical websites.

Every row is the same drug. If a source uses any of these names, it is talking about what Lilly now sells as Foundayo.

Where each name came from

Let's break it down in the order the names appeared, because each one marks a stage in the drug's life.

The codes: OWL833 and LY3502970

Orforglipron was discovered by Chugai Pharmaceutical in Japan and licensed to Lilly in 2018, as Lilly states in its own product description. Chugai's internal code was OWL833, and the FDA's 2026 review still labels several laboratory tables with it. Once Lilly took over, the compound became LY3502970, the code you will still see on trial registrations at ClinicalTrials.gov to this day.

Codes exist because a company does not want to spend money naming something that will probably fail. Most early compounds never reach patients, so a generic name only gets requested once a drug looks worth the trouble.

The generic name: why "-glipron"

Generic names are not invented from scratch. The World Health Organization's International Nonproprietary Names programme builds them from a random-sounding prefix plus a stem that tells clinicians what class the drug belongs to. WHO's February 2026 addendum to its stem book lists -glipron under antihyperglycaemics, with the plain definition "glucagon-like peptide 1 receptor (GLP1R) agonists". Orforglipron is one of nine names on that list, alongside danuglipron, lotiglipron and six newer compounds.

So "orfor" is the unique part, and "glipron" says what the drug does. Here is how that compares with the stems behind the injectable GLP-1 drugs Canadians already know.

Our take: the stem is the most honest clue in the whole name. Every -glutide drug is a peptide, which is why most of them are injected. Orforglipron is a small molecule, and the naming system gave it a stem with no "-tide" in it. You can read the drug's class from its name before you read a word about its chemistry.

The brand name: Foundayo

Lilly has not published an explanation of what Foundayo means, and we would not trust anyone who claims to know. What we can say is that it was checked. The FDA's multidisciplinary review lists FOUNDAYO as the proposed trade name next to the code LY3502970, and records that the agency's Division of Medication Error Prevention and Analysis found the name "conditionally acceptable" for the product. Approval followed on 1 April 2026.

How do you pronounce Foundayo and orforglipron?

After "what is the orforglipron brand name?", this is the question people ask most, and with good reason. Futurism ran a 2025 piece calling orforglipron a candidate for the worst drug name ever. Fair or not, it is a mouthful.

• Foundayo: fown-DAY-oh. Lilly prints that respelling in the US safety summary attached to its September 2026 press releases, so treat it as official.
• Orforglipron: or-for-GLIP-ron. That is the respelling Futurism used, with the stress on the stem. No regulator publishes an official respelling for generic names, so treat this one as common usage rather than a rule.
• LY3502970: people just read out the letters and digits.

Here is why pronunciation is more than trivia. If you tell a pharmacist or a doctor the name, you want them to hear the right drug. That worry is exactly what regulators test for when they review a brand name, which brings us to the next part.

How a drug's brand name gets approved

A company cannot just print any name it likes on a prescription drug. In both the US and Canada the name is reviewed alongside the drug, mainly to stop medication errors.

The FDA name review

In the US, proposed names go to the FDA's Division of Medication Error Prevention and Analysis. The agency's December 2020 guidance on proprietary names says its aim is to cut name-related medication errors and to keep out names that would break US drug law, such as misleading ones. It also shares the framework FDA reviewers use, so companies can test names before they submit them. The orforglipron brand name passed that screen, as the FDA review records.

Health Canada's look-alike sound-alike review

Canada does its own check, and it does not simply copy the FDA. Health Canada's guidance on reviewing drug brand names, released in July 2014, asks sponsors to test whether a proposed name could be confused with any product already authorised in Canada. That is called a look-alike sound-alike (LASA) assessment. A full one involves:

• searching Canada's Drug Product Database and natural health product database for similar names;
• simulations of prescribing and dispensing with at least 100 Canadian health professionals;
• a French-speaking share of 20 to 25% of those participants, because names get spoken in both official languages;
• a failure analysis of how a mix-up could happen and what harm would follow.

The guidance says plainly that a LASA assessment done in another jurisdiction "may" need more work "to reflect the Canadian context". If every proposed name fails and the sponsor will not fall back on the generic name, Health Canada issues a Notice of Non-compliance. So a brand name can hold up a Canadian approval on its own. That is rare, but it is written into the rules.

Will Foundayo get a different name for diabetes?

This is the question we get most from readers who know Lilly's history. Lilly sells tirzepatide under two brands. The FDA's 2023 approval notice for Zepbound spells it out: tirzepatide was "already approved under the trade name Mounjaro" for type 2 diabetes, and Zepbound became the weight management brand. Canada now has both brands too. Health Canada authorised Zepbound for chronic weight management in July 2025, according to Lilly Canada.

So you might expect a second orforglipron brand name for diabetes. The evidence so far points the other way:

• The UK's Medicines and Healthcare products Regulatory Agency authorised orforglipron on 10 August 2026 for weight management and type 2 diabetes in one go, under the single name Foundayo.
• Lilly's 30 September 2026 announcement of the ACHIEVE-4 diabetes trial calls the study drug Foundayo throughout, not a new name.
• In the US, Foundayo is approved for weight management only. The diabetes use has no separate US brand on record.

Our take: we would not bet on a second brand. One name across both uses looks like Lilly's plan, at least in the UK. But the US has no diabetes approval yet, and a company can change course, so treat this as a strong lean rather than a fact.

Will Canada use the Foundayo brand name?

Probably, but nobody can confirm it yet. Here is what is known and what is not, with the detail on availability left to our page on Foundayo's status in Canada.

We think Foundayo is the likely Canadian orforglipron brand name, because Lilly kept it in the UK and because a global brand is cheaper to run. What we cannot rule out is a Canadian name clash we cannot see from outside, since the LASA files are not public. Our Canadian orforglipron tracker will note the brand on the day a Notice of Compliance names it.

Look-alike names and fake "orforglipron" online

Names matter most when someone is trying to sell you something. Here is what to watch.

Names that get mixed up

The obvious confusion is between orforglipron and the other -glipron names. Two of them belonged to Pfizer pills that were dropped: lotiglipron in June 2023 and danuglipron in April 2025, both after liver signals in trials. Neither is a version of Foundayo, and neither is sold. Another easy mistake is assuming Foundayo is a form of semaglutide because it is a GLP-1 pill like Rybelsus. It is not. It is a different molecule from a different company, and our Foundayo and Rybelsus comparison sets the two side by side.

Research chemicals and counterfeits

Search the generic name and you will find chemical suppliers listing orforglipron powder under the codes LY3502970 and OWL833, with warnings that the product is not for human use. Those listings are for lab work. They are not a cheaper way to get the drug, and nothing about their purity, dose or storage is checked for people.

Health Canada's January 2026 advisory on fake and unauthorised GLP-1 products names Ozempic, Wegovy, Mounjaro and Zepbound, and the same risks apply to anything sold as orforglipron. The regulator warns these products can hold the wrong amount of active ingredient, unlisted ingredients, or contaminants. Its advice is simple:

• look for an eight-digit Drug Identification Number (DIN) on the package;
• check that DIN in the Drug Product Database;
• buy only from licensed pharmacies.

Right now no orforglipron product has a Canadian DIN, because none is authorised. That makes the test easy: any product sold in Canada as orforglipron or Foundayo today fails it. We do not link to sellers, and we would not trust one that claims a Health Canada endorsement.

One more check helps if someone shows you "Foundayo" from the US. The FDA label describes genuine tablets: round tablets debossed "L" on one side for the three lowest strengths, and modified ovals debossed "Lilly" for the three highest, each with a G1 to G6 code on the other side. A tablet that does not match is a red flag. If you ever take something you suspect is fake, talk to a doctor or pharmacist and report it to Health Canada.

Which orforglipron name should you search?

It depends on what you need. Next steps:

• Foundayo for the product as people use it now: US pricing, patient experience, pharmacy news.
• Orforglipron for trial results, journal papers and every Canadian regulatory file, since both Health Canada and Canada's Drug Agency list the generic name.
• LY3502970 for trial registrations and older research.

For a Canadian reader, the generic name is the one that will tell you when the drug actually arrives. Our dated review timeline follows those filings step by step, and the orforglipron brand name will appear there the moment Health Canada makes it official.